Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations - PubMed
4 hours ago
- #KIT Exon 9 Mutations
- #Imatinib
- #Gastrointestinal Stromal Tumors
- Adjuvant imatinib was studied in patients with resected GISTs harboring KIT exon 9 mutations.
- The study included 367 patients from 35 referral centers in Europe, the US, and Japan.
- Adjuvant imatinib was associated with reduced early recurrence or death (HR, 0.19; 95% CI, 0.10-0.36).
- Improved overall survival was also observed (HR, 0.37; 95% CI, 0.17-0.83).
- No significant difference was found between 400 mg/d and 800 mg/d dosing in high-risk patients.
- The findings support the use of adjuvant imatinib in high-risk GISTs with KIT exon 9 mutations.